Welcome to our dedicated page for Hookipa Pharma SEC filings (Ticker: HOOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding HOOKIPA Pharma’s cutting-edge arenavirus science is challenging enough—digging through dense SEC filings shouldn’t add to the workload. Clinical trial readouts, partnership milestones, and rapid cash burn details hide in hundreds of pages, and tracking HOOKIPA Pharma insider trading Form 4 transactions in real time is even tougher. If you’ve ever wondered, “How do I locate the next HOOKIPA Pharma quarterly earnings report 10-Q filing or the latest 8-K material events explained?” you’re in the right place.
Stock Titan pairs every HOOK filing with AI-powered summaries that translate biotech jargon into plain English. Our platform flags cash-runway updates inside the HOOKIPA Pharma annual report 10-K simplified, highlights pipeline progress in each HOOKIPA Pharma earnings report filing analysis, and surfaces HOOKIPA Pharma executive stock transactions Form 4 within minutes of submission. Prefer raw documents? Access complete 10-K, 10-Q, 8-K, 20-F, S-1, and even HOOKIPA Pharma proxy statement executive compensation disclosures—plus HOOKIPA Pharma Form 4 insider transactions real-time—without leaving the page.
Whether you’re comparing quarter-over-quarter R&D spend, monitoring insider buying before trial milestones, or simply understanding HOOKIPA Pharma SEC documents with AI, our coverage delivers. Investors routinely use the platform to:
- Spot dilution risks hidden in shelf registrations
- Track trial setbacks or breakthroughs announced via 8-K
- Study segment cash flows in each HOOKIPA Pharma quarterly earnings report 10-Q filing
HOOKIPA Pharma Inc. (NASDAQ: HOOK) has called a virtual special meeting for 10:00 a.m. ET on July 29, 2025 to seek shareholder approval for three critical proposals:
- Asset Sale (Proposal 1): Sale of all assets related to the HB-400 (Hepatitis B) and HB-500 (HIV) programs, including IP and know-how, to long-time collaborator and 5%+ shareholder Gilead Sciences for up to $10 million cash ( $3 million at closing plus up to $7 million in three post-closing transfer-plan tranches).
- Dissolution (Proposal 2): Liquidation of the company pursuant to a Plan of Dissolution, conditional upon successful closing of the Asset Sale.
- Adjournment (Proposal 3): Authority to adjourn the meeting if additional proxy solicitation is required.
The Board unanimously recommends voting “FOR” all proposals.
Key financial terms
- Estimated net proceeds from the transaction: $7.6 million after taxes and expenses, assuming full $10 million consideration is earned.
- Board projects liquidating distributions of approximately $1.28 – $1.72 per common and Class A share (based on 12.2 million diluted shares) but no earlier than three years after filing the Certificate of Dissolution.
- If the Transfer Plan phases are disputed, related cash installments may be delayed or forfeited, and the company cannot file its dissolution certificate until all phases are accepted or waived.
- No appraisal or dissenters’ rights apply.
Strategic rationale
- Limited cash, no marketed products, rising public-company costs and historically low trading liquidity led the Board to pursue a sale after a year-long strategic review that included but ultimately rejected an alternative transaction with Poolbeg Pharma.
- Transaction allows monetisation of non-core infectious-disease programs while providing shareholders an exit path.
Process & governance
- Majority of outstanding common shares (≈4.9 million) must vote “FOR” to pass Proposals 1 and 2.
- Executive officers and directors will receive accelerated vesting of 178,570 RSUs and 13,264 options upon closing.
- Failure to approve the Dissolution does not block the Asset Sale, but would leave HOOK with no active programs or clear strategy.
Timeline
- Closing targeted as soon as regulatory clearance (Austrian FDI filing) and shareholder approval obtained, but outside deadline is Nov 21 2025.
- Transfer books will close on the “Final Record Date” when the Certificate of Dissolution is filed; shares are expected to be delisted from Nasdaq shortly after the special meeting.
AeroVironment, Inc. (Nasdaq: AVAV) has filed a preliminary prospectus supplement (Form 424B5) for a public offering of $750 million of common stock, with a 30-day underwriters’ option for up to an additional $112.5 million. The company is simultaneously marketing a separate $600 million (up to $690 million) offering of Convertible Senior Notes due 2030. Neither transaction is contingent on the other.
Key transaction terms
- Common stock trades on Nasdaq under the symbol “AVAV”; last reported price on 27-Jun-2025 was $278.07.
- Pro-forma share count will rise to 48,511,437 immediately after the equity offering (from 45,814,275).
- Underwriters: J.P. Morgan Securities LLC and BofA Securities, Inc.; their banking affiliates are lenders under the company’s credit facilities and will receive a portion of the proceeds.
Use of proceeds
- $700.2 million to repay outstanding borrowings under the New Term Loan (matures 1-May-2027).
- $265.1 million to repay borrowings on the Revolving Credit Facility (matures 4-Oct-2029).
- Any remainder for general corporate purposes, including increased manufacturing capacity.
Strategic backdrop – BlueHalo merger
- AeroVironment closed the all-stock acquisition of BlueHalo on 1-May-2025, issuing 17,425,849 shares and drawing $925 million of debt to retire BlueHalo obligations and pay transaction costs.
- Lock-up agreements restrict resale of the BlueHalo shares until May-2026 (40%), Nov-2026 (30%) and May-2027 (30%).
Recent financial performance
- Quarter ended 30-Apr-2025 GAAP EPS: $0.59; Non-GAAP EPS: $1.61.
- FY-2025 GAAP EPS: $1.55; Non-GAAP EPS: $3.28.
- FY-2025 Adjusted EBITDA: $146.4 million, up from $127.8 million in FY-2024.
- Q4-2025 goodwill impairment charge: $18.4 million.
Capitalisation impact
- As-adjusted cash rises to $454.1 million; total debt falls from $955.0 million to $600.0 million if both offerings close and proceeds are applied as planned.
- Total shareholders’ equity would rise from $886.5 million to $4.23 billion (reflecting BlueHalo equity issuance and the new share sale).
Risk highlights
- Approximately 5–6 % dilution to existing shareholders from the equity issuance, with further dilution possible from note conversion.
- Successful integration of BlueHalo is critical; merger-related synergies and cost savings are not assured.
- If the note offering is unsuccessful, AeroVironment may retain higher leverage until alternative funds are secured.
Overall, the combined equity and convertible offerings are designed to deleverage the balance sheet after the transformational BlueHalo merger, provide funding for capacity expansion, and position the company for growth across autonomous systems, precision-strike and other defense technology markets.
FAQ
What is the current stock price of Hookipa Pharma (HOOK)?
What is the market cap of Hookipa Pharma (HOOK)?
What core technology does HOOKIPA Pharma utilize?
Which therapeutic areas are the focus of HOOKIPA Pharma?
How does HOOKIPA Pharma differentiate its approach in immunotherapy?
What is the significance of HOOKIPA Pharma's viral vectors?
Does HOOKIPA Pharma collaborate with other companies?
What distinguishes HOOKIPA Pharma's immunotherapeutic approach?
How does HOOKIPA Pharma ensure transparent communication with stakeholders?
